Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
D000077284:Abciximab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology; D000918:Antibody Specificity; D002986:Clinical Trials as Topic; D000939:Epitopes / Q000276:immunology; D000077542:Eptifibatide; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000276:immunology; D051379:Mice; D009203:Myocardial Infarction / Q000139:chemically induced; D010455:Peptides / Q000009:adverse effects / Q000276:immunology; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000187:drug effects / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology
D000911:Antibodies, Monoclonal; D000939:Epitopes; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011993:Recombinant Fusion Proteins; D014443:Tyrosine; D005340:Fibrinogen; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab